This proposed rule would codify the Medicare Drug Price Negotiation Program ("Negotiation Program") and would establish certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program as required by the Inflation Reduction Act of 2022. This proposed rule would also propose a modification to the fixed combination drug policy.
US Federal Register - CMS Rules · June 16, 2026
Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
Proposed rule to codify the Medicare Drug Price Negotiation Program and establish new policies for drug pricing and the prescription drug benefit under the Inflation Reduction Act.
Published by US Federal Register - CMS Rules. HealthSignal links to the original document; the summary above is extracted from the source text.